��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Cancer Risk associated with Disease-Modifying Drugs in Multiple Sclerosis: a French Registry-based Study

Topic General Neurology

Presentation(s) (-)

Poster/Presentation
Number 102

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
Nathalie Derache (Hopital Cote De Nacre)	Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MERCK. Nathalie Derache has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Gilles Defer, MD (Hopital Cote De Nacre)	Dr. Defer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Defer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen . Dr. Defer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis . Dr. Defer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche.
Deniz Erten-Lyons, MD, FAAN (FDA)	Dr. Erten-Lyons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acadia Pharamceuticals.